EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2

Tilman Läppchen iD, Adrianna Bilinska, Eirinaios Pilatis, Elena Menéndez, Surachet Imlimthan iD, Euy Sung Moon, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger iD, Eleni Gourni

Molecules · 28.06.2024 · 29 (13) · 3093

DOI: 10.3390/molecules29133093 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Molecules, online erschienen am 28.06.2024. Verfasst von Tilman Läppchen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Inselspital, Bern University Hospital, 3010 Bern, Switzerland. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes, Radiopharmaceuticals, Gallium Radioisotopes. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon Europe Research and Innovation programme under the Marie Skłodowska-Curie Action, European Union’s Horizon Europe Research and Innovation program under the Marie Skłodowska-Curie Action (OncoProTools).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

FAP radiopharmaceuticals show promise for cancer diagnosis; however, their limited tumor residency hinders treatment. This study compared two FAPi derivatives, DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2, labeled with gallium-68 and lutetium-177, aiming to determine an optimum combination for creating theranostic pairs.

Methods

The radiotracers were studied for lipophilicity, binding to human serum proteins, and binding to human cancer-associated fibroblasts (CAFs) in vitro, including saturation and internalization/externalization studies. PET/SPECT/CT and biodistribution studies were conducted in PC3 and U87MG xenografts for [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTAGA.(SA.FAPi)2. [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2, were evaluated in PC3 xenografts. Biodistribution studies of [68Ga]Ga-DOTA.SA.FAPi were performed in healthy male and female mice.

Results

All radiotracers exhibited strong binding to FAP. Their internalization rate was fast while only [177Lu]Lu-DOTAGA.(SA.FAPi)2 was retained longer in CAFs. [68Ga]Ga-DOTAGA.(SA.FAPi)2 and [177Lu]Lu-DOTAGA.(SA.FAPi)2 displayed elevated lipophilicity and affinity for human serum proteins compared to [68Ga]Ga-DOTA.SA.FAPi and [177Lu]Lu-DOTA.SA.FAPi. In vivo studies revealed slower washout of [68Ga]Ga-DOTAGA.(SA.FAPi)2 within 3 h compared to [68Ga]Ga-DOTA.SA.FAPi. The tumor-to-tissue ratios of [68Ga]Ga-DOTAGA.(SA.FAPi)2 versus [68Ga]Ga-DOTA.SA.FAPi did not exhibit any significant differences. [177Lu]Lu-DOTAGA.(SA.FAPi)2 maintained a significant tumor uptake even after 96 h p.i. compared to [177Lu]Lu-DOTA.SA.FAPi.

Conclusions

Dimeric compounds hold promise for therapy, while monomers are better suited for diagnostics. Finding the right combination is essential for effective disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumRadioisotopesRadiopharmaceuticalsGallium RadioisotopesEndopeptidasesHumansAnimalsMiceTissue DistributionCell Line, TumorMembrane ProteinsGelatinasesHeterocyclic Compounds, 1-RingFemaleMaleTheranostic NanomedicineFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

FAPi-dimerFAPi-monomerfibroblast activation protein inhibitors (FAPi)gallium-68lutetium-177

Substanzen

LutetiumRadioisotopesRadiopharmaceuticalsGallium RadioisotopesEndopeptidasesMembrane ProteinsGelatinasesHeterocyclic Compounds, 1-RingFibroblast Activation Protein AlphaLutetium-177

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
  • Department of Chemistry-TRIGA Site, Johannes Gutenberg-University Mainz, 55128 Mainz, Germany.

ORCID-Profile: Tilman Läppchen, Surachet Imlimthan, Axel Rominger

Förderung

  • European Union's Horizon Europe Research and Innovation programme under the Marie Skłodowska-Curie Action
  • European Union’s Horizon Europe Research and Innovation program under the Marie Skłodowska-Curie Action (OncoProTools)

Zitieren

APA

Läppchen, T., Bilinska, A., Pilatis, E., Menéndez, E., Imlimthan, S., Moon, E. S., Afshar-Oromieh, A., Rösch, F., Rominger, A., & Gourni, E. (2024). Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2. Molecules, 29(13), 3093. https://doi.org/10.3390/molecules29133093

Vancouver

Läppchen T, Bilinska A, Pilatis E, Menéndez E, Imlimthan S, Moon ES, et al. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2. Molecules. 2024;29(13):3093. doi:10.3390/molecules29133093

BibTeX
@article{Lppchen2024,
  author = {Läppchen, Tilman and Bilinska, Adrianna and Pilatis, Eirinaios and Menéndez, Elena and Imlimthan, Surachet and Moon, Euy Sung and Afshar-Oromieh, Ali and Rösch, Frank and Rominger, Axel and Gourni, Eleni},
  title = {Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2},
  journal = {Molecules},
  year = {2024},
  volume = {29},
  number = {13},
  pages = {3093},
  doi = {10.3390/molecules29133093}
}
Kostenlos starten →